» Articles » PMID: 19221501

Systemic Targeting of Primary Bone Tumor and Lung Metastasis of High-grade Osteosarcoma in Nude Mice with a Tumor-selective Strain of Salmonella Typhimurium

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2009 Feb 18
PMID 19221501
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

We report here a new targeting strategy for primary bone tumor and lung metastasis with a modified auxotrophic strain of Salmonella typhimurium. We have previously developed the genetically-modified strain of S. typhimurium, selected for tumor targeting and therapy in vivo. Normal tissue is cleared of these bacteria even in immunodeficient athymic mice with no apparent side effects. In this study, the tumor-targeting strain of S. typhimurium, termed A1-R, was administered i.v. to nude mice which have primary bone tumor and lung metastasis. Primary bone tumor was obtained by orthotopic intra-tibial injection of 5 x 10(5) 143B-RFP (red fluorescent protein) human osteosarcoma cells. One group of mice was treated with A1-R expressing GFP (green fluorescent protein) and another group was used a as control. A1-R (5 x 10(7) colony-forming units) was injected in the tail vein three times on a weekly basis. On day 28, lung samples were excised and observed with the Olympus OV100 Small Animal Imaging System. The size of the primary tumor and RFP intensity of lung metastasis were measured. Primary bone tumor size (fluorescence area [mm(2)]) was 232 +/- 70 in the untreated group and 95 +/- 23 in the treated group (p < 0.05). RFP intensity of the lung metastasis was 3 +/- 1.5 x 10(6) in the untreated group and 0.42 +/- 0.33 x 10(6) in the treated group (p < 0.05). Therefore, bacterial treatment was effective for both primary bone tumor and lung metastasis.

Citing Articles

Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude Mice.

Morinaga S, Zhao M, Mizuta K, Kang B, Bouvet M, Yamamoto N In Vivo. 2025; 39(2):640-647.

PMID: 40010967 PMC: 11884439. DOI: 10.21873/invivo.13869.


The Combination of Tumor-targeting A1-R Plus the Autophagy-inhibitor Chloroquine Synergistically Eradicates HT1080 Fibrosarcoma Cells and .

Morinaga S, Zhao M, Mizuta K, Kang B, Bouvet M, Yamamoto N In Vivo. 2024; 39(1):102-109.

PMID: 39740880 PMC: 11705149. DOI: 10.21873/invivo.13807.


Accurate and Safe Tumor Targeting of Orally-administered A1-R Leads to Regression of an Aggressive Fibrosarcoma in Nude Mice.

Morinaga S, Zhao M, Mizuta K, Kang B, Sato M, Bouvet M In Vivo. 2024; 38(6):2601-2609.

PMID: 39477429 PMC: 11535920. DOI: 10.21873/invivo.13736.


Bacteria-Based Nanoprobes for Cancer Therapy.

Lu Y, Mei N, Ying Y, Wang D, Li X, Zhao Y Int J Nanomedicine. 2024; 19:759-785.

PMID: 38283198 PMC: 10821665. DOI: 10.2147/IJN.S438164.


and outer membrane vesicles are current and future options for cancer treatment.

Jorge G, Gontijo M, Brocchi M Front Cell Infect Microbiol. 2023; 13:1293351.

PMID: 38116133 PMC: 10728604. DOI: 10.3389/fcimb.2023.1293351.